476620-54-9

Basic information

• Product Name: 2-Bromo-4,5-difluorobenzaldehyde
• Synonyms: 2-Bromo-4,5-difluorobenzaldehyde
• CAS NO: 476620-54-9
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 220.9989264
• Mol File: 476620-54-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 232.0±35.0 °C(Predicted)
• Appearance: Off-white/Powder
• Density: 1.758±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-Bromo-4,5-difluorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4,5-difluorobenzaldehyde(476620-54-9)
• EPA Substance Registry System: 2-Bromo-4,5-difluorobenzaldehyde(476620-54-9)

Safety Data

• Hazardous Substances Data: 476620-54-9(Hazardous Substances Data)

Usage

Uses

It is an important intermediate for pharmaceutical and organic synthesis.

Upstream product

• 64695-78-9 1,2-difluoro-4,5-dibromobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 64695-84-7 2-bromo-4,5-difluorobenzoic acid 
• 476620-55-0 (2-bromo-4,5-difluorophenyl)methanol 

Downstream Products

• 1266728-05-5 2-(2-bromo-4,5-difluorophenyl)-1,3-dioxane 
• 1307795-09-0 2-(2-bromo-4,5-difluorophenyl)-1,3-dioxolane 
• 1307795-06-7 bromo[2-(1,3-dioxalan-2-yl)-4,5-difluorophenyl]magnesium 
• 959687-70-8 1-bromo-4,5-difluoro-2-(dimethoxymethyl)benzene 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Synthesis and Transformations of Functionalized Benzosiloxaboroles

The synthesis and characterization of a series of fluorinated benzosiloxaboroles bearing synthetically useful formyl and cyano groups is reported. These compounds have been obtained by multistep syntheses starting with simple halogenated benzenes. The general synthetic protocol was based on the generation of ortho-boronated aryldimethylsilanes which undergo dehydrogenative cyclization upon hydrolytic workup due to activation of the Si–H bond by the adjacent boronic group. In some cases the synergy of adjacent boron- and silicon-based functionalities resulted in an unexpected hydrosilylation of the CHO group under mild aqueous conditions. The reduction of a benzosiloxaborole derivative bearing the formyl group at the ortho position with respect to the boron atom resulted in a structural transformation reflecting the higher stability of the carboxaborole heterocycle with respect to its silicon counterpart. Thus, a unique heterocyclic system featuring a central 10-membered ring comprising two borasiloxane linkages was isolated.

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.